부산대학교 도서관

Background: The thiazolidinediones (TZDs) form a new class of antidiabetes medication that enhances the actions of insulin in muscle, liver, and adipose tissue. This study investigated the effects of rosiglitazone (ROS), a TZD, on glycemic control in type 2 diabetic patients, poorly controlled with maximum doses of sulfonylurea given alone or in combination with maximum tolerated doses of metformin and/or acarbose. Methods: We investigated 77 type 2 diabetic patients with a fasting plasma glucose (FPG) of more than 10 mmol/L and Hemoglobin A1c (HbA1c) levels at least 8.0%. The patients were divided into 3 groups: Group 1, sulfonylurea alone (n=11); Group 2, sulfonylurea combined with metformin (n=52); and Group 3, sulfonylurea combined with metformin and acarbose (n=14). All participants received 4 mg ROS once daily for 12 weeks. Results: At the completion of therapy, there were significant reductions in FPG concentration in patients of Group 2 (12.03 ±0.52 mmol/L vs 9.76±0.59 mmol/L, p＜0.005) and Group 3 (12.95±1.42 mmol/L vs 10.19±1.17 mmol/L, p＜0.05), and a slight but not significant reduction in Group 1 (12.47±1.35 mmol/L vs 11.26±1.16 mmol/L, p=0.43). HbA1c levels were markedly reduced in all 3 groups (Group 1, 10.3±0.2% vs 9.8±0.4%, p＜0.05; Group 2, 10.4±0.2% vs 9.3±0.3%, p＜0.001; Group 3, 10.5±0.5% vs 9.2±0.6%, p＜0.001). Conclusions: The addition of ROS is effective in improving glycemic control in type 2 diabetic patients poorly controlled with other oral hypoglycemic agents.